Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.80 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23043270 | 1.00 | TDP1 (0.80) | TDP1CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9540610 | 1.00 | TDP1 (0.80) | TDP1CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19317460 | 1.00 | TDP1 (0.80) | TDP1CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL29366521 | 1.00 | TDP1 (0.80) | TDP1CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9040301 | 0.93 | TDP1 (0.84) | TDP1CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16757274 | 0.93 | TDP1 (0.91) | TDP1 | |
| SCHEMBL31501784 | 0.93 | TDP1 (0.91) | TDP1 | |
| Lupinine SCHEMBL2633852 | 0.89 | TDP1 (1.00) | TDP1 | |
| Lupinine SCHEMBL914675 | 0.89 | TDP1 (1.00) | TDP1 | |
| Lupinine SCHEMBL177708 | 0.89 | TDP1 (1.00) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357686-B2 | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-RE43390-E1 | Pleuromutilin derivatives as antimicrobials | GLAXOSMITHKLINE LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-8163741-B2 | Use of aryl-substituted polycyclic amines as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-04-24 | — | — | US | disclosed |
| EP-1930330-B1 | Pleuromutilin derivatives as antimicrobials | SMITHKLINE BEECHAM LTD (GB) | 2011-09-21 | — | — | EP | disclosed |
| EP-2323651-A2 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | Summit Corporation Plc (GB) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010029313-A1 | ANTIINFECTIVE COMPOUNDS | SUMMIT CORPORATION PLC. (GB) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010015815-A2 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2010-02-11 | — | — | WO | disclosed |
| US-20090258881-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258872-A1 | USE OF ARYL-SUBSTITUTED POLYCYCLIC AMINES AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| US-7569583-B2 | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| EP-1781656-B1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-20070197584-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1781656-A2 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Sanofi-Aventis Deutschland GmbH (DE) | 2007-05-09 | — | — | EP | disclosed |
| US-RE39128-E1 | ANTIBACTERIA DRUG; RESPIRATORY SYSTEM DISORDERS; OTITIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-06-13 | — | — | US | disclosed |
| WO-2006018279-A2 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-02-23 | — | — | WO | disclosed |
| EP-1028961-B1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-29 | — | — | EP | disclosed |
| EP-1452534-A1 | PLEUROMUTLIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-01 | — | — | EP | disclosed |
| US-6281226-B1 | Pleuromutilin derivatives as antimicrobials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-28 | — | — | US | disclosed |
| EP-1028961-A1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999021855-A1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197584-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | PAH, NAT1, AADAT | TDP1 2402/4885CHRM4 2104/4885CHRM5 1326/4885 |
| US-20090258872-A1 | USE OF ARYL-SUBSTITUTED POLYCYCLIC AMINES AS MEDICAMENTS | AADAT, NAT1, OAT | TDP1 1792/4885CHRM4 1711/4885CHRM5 834/4885 |
| US-20090258881-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | PAH, NAT1, AADAT | TDP1 2402/4885CHRM4 2104/4885CHRM5 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.